Neurosurg Focus 40 (6): E14, 2016 D egenerative cervical myelopathy (DCM) is a progressive degenerative spine condition and is the most common cause of spinal cord dysfunction in adults worldwide.
trinsic hand muscles, and gait dysfunction. 29 Patients with DCM may have substantial functional impairment, significantly reduced quality of life, and be unable to perform certain activities of daily living.
Surgery is typically recommended as the preferred management strategy for patients with clinical and imaging evidence of DCM. 5, 8 In general, surgical decompression of the cervical spine is effective at halting neurological deterioration, relieving certain symptoms, and improving functional status and quality of life. The minimum clinically important difference (MCID) is defined as the minimum change in a measurement that a patient would identify as beneficial. 3, 19, 20 Based on two recent prospective studies, patients, on average, exhibited a 2.40-to 2.88-point gain on the modified Japanese Orthopaedic Association (mJOA) scale following surgery, an improvement exceeding the overall MCID for this metric (2 points). 2, 5, 8, 28 The MCID of the mJOA scale, however, varies based on preoperative myelopathy severity: 1 point for mild myelopathy (mJOA ≥ 15), 2 points for moderate myelopathy (mJOA score of [12] [13] [14] , and 3 points for severe disease (mJOA score < 12). 28 Before undergoing surgery, patients are likely to inquire about the ultimate goals of the operation and of their chances of experiencing meaningful improvements in functional status. Although several highquality prognostic studies exist in the literature, no study has examined important predictors of achieving an MCID on the mJOA scale. This knowledge is critically important to patients and is essential to appropriately manage their expectations regarding the outcomes of surgery, increase satisfaction, and provide decision-making support to surgeons.
The objective of this study was to define significant predictors of achieving an MCID on the mJOA scale at 2 years following surgery for the treatment of DCM.
Methods

Patients
Seven hundred fifty-seven patients were prospectively enrolled in either the AOSpine North America (n = 278) or International (n = 479) study at 26 global sites. Centers were asked to participate if they were either high-volume private practices or academic institutions and if they had experience conducting prospective clinical research. Investigators were neurosurgeons or orthopedic spine surgeons. Ethical approval was obtained from each site's institutional review board.
The inclusion criteria for both studies were identical: 1) age 18 years or older; 2) symptomatic DCM with at least one clinical sign of myelopathy; 3) imaging evidence of cervical cord compression; and 4) no previous cervical spine surgery. Patients were excluded if they were asymptomatic or had a diagnosis of active infection, neoplastic disease, rheumatoid arthritis, ankylosing spondylitis, or concomitant symptomatic lumbar stenosis. Verbal and written informed consent was obtained from each participant.
Surgical Intervention
All patients underwent surgical decompression of the cervical spine. The attending surgeon decided what approach to use, the number of levels to operate on, and whether to use fusion or instrumentation. Patients were either treated anteriorly, posteriorly, or with a 2-stage anterior-posterior surgery. Anterior techniques included discectomy and/or corpectomy with fusion. Patients operated on posteriorly underwent either laminectomy with or without fusion or laminoplasty.
Data Collection
Extensive data were collected for each participant, including demographic information, symptomatology, medical history, causative pathology and surgical summary. Each patient was clinically examined at baseline and at 6-, 12-, and 24-month intervals following surgery. Functional impairment was measured using the mJOA and Nurick scales, disability was evaluated using the Neck Disability Index, and quality of life was assessed using the SF-36 version 2.
The primary outcome measure for this study was the mJOA score. The mJOA scale is an investigator-administered DCM-specific index that separately addresses motor function of the upper and lower extremities, sensory function of the upper extremities, and sphincter function. A score of 18 indicates normal function, whereas a lower score reflects more severe neurological impairment. Kopjar et al., 13 in 2015, evaluated the psychometric properties of this scale and reported that it is composed of two dimensions, has moderate internal consistency, is responsive to change, and demonstrates both convergent and divergent validity. The reliability of the mJOA scale has not been established; however, the inter-and intrarater reliabilities of the JOA scale are high.
External Monitoring
External research monitors performed onsite evaluations to ensure that the data were accurate, reliable, and complete and that the study was conducted in compliance with the protocol. All data were transcribed into an electronic data capture system and were processed at the AOSpine clinical research network data management center.
Statistical Analysis
Continuous variables were described using means, standard deviations, and ranges. Categorical variables were summarized using frequencies and percentages.
A last-observation-carry-forward approach was used to impute missing data at 24 months. Change in mJOA score was calculated by subtracting a patient's preoperative score from his/her 24-month follow-up score. An "optimal" outcome was defined as a change in mJOA score greater than or equal to the MCID of this scale. For patients with severe myelopathy (mJOA score < 12), the MCID is 3 points; for those with moderate disease (mJOA score of [12] [13] [14] , the MCID is 2 points; and for those with mild disease (mJOA score ≥ 15), the MCID is 1 point. A "suboptimal" outcome was classified as a change in mJOA score that was less than the MCID, no change in status, or functional deterioration.
Univariate log-binomial regression analyses were conducted to evaluate the association between several pre-operative factors and surgical outcomes. Variables that yielded a p value < 0.20 in univariate analysis were further examined in a multivariate analysis. Variables that were considered clinically relevant but had a p value > 0.2 were also assessed in multivariate analyses. Multicollinearity was evaluated by calculating tolerance. Modified Poisson regression using robust error variances was used to create the final multivariate model and compute the relative risk for each predictor.
Results
Patients
Four hundred one participants (52.97%) were enrolled at sites in North America (278 from North American study, 123 from International study), 150 (19.82%) in Asia Pacific, 126 (16.64%) in Europe, and 80 (10.57%) in Latin America. Of these 757 participants, 14 were excluded from this analysis because they scored the maximum preoperative mJOA score of 18. Table 1 summarizes enrollment by site.
Our cohort consisted of 463 (62.31%) men and 280 (37.69%) women, with an average age of 56.48 ± 11.85 years (range 21-87 years). Patients presented with a wide array of neurological signs and symptoms, including hyperreflexia (77.90%), corticospinal distribution motor deficits (62.80%), numb hands (89.49%), weakness (82.88%), and gait impairment (76.55%). The average baseline mJOA score was 12.52 ± 2.74 (range 3-17 points), with 193 presenting with mild myelopathy (mJOA score of 15-17), 296 with moderate disease (mJOA score of [12] [13] [14] , and 254 with severe disease (mJOA score < 12). Four hundred fifty-nine patients (61.78%) suffered from comorbidities, with the most common being cardiovascular (44.95%), endocrine (18.17%), and gastrointestinal (16.15%) disorders. With respect to causative pathology, 77.25% of patients displayed evidence of spondylosis, 71.74% of disc herniation, and 24.23% of a hypertrophied ligamentum flavum. A smaller percentage of patients presented with ossification of the posterior longitudinal ligament (21.13%) and subluxation (5.79%).
All 743 patients underwent surgical decompression of their cervical spine: 436 (58.68%) were treated anteriorly, 284 (38.22%) posteriorly, and 23 (3.10%) underwent a 2-stage anterior-posterior surgery. The mean number of decompressed segments was 3.74 ± 1.27 (range 1-7 levels), and the mean operative duration was 180.70 ± 80.03 minutes (range 45-575 minutes). Table 2 displays a complete summary of the demographics and surgical characteristics of patients enrolled in the International and North American studies.
24-Month Follow-Up
Five hundred fifty (74.02%) of the 743 patients attended their 2-year follow-up visit and were evaluated for improvements in functional status (mean mJOA score 15.34 ± 2.64, range 7-18). Following imputation, mJOA data were available for 687 participants (92.46%) (mean mJOA score 15.26 ± 2.77, range 2-18). The mean change in functional status was 2.71 ± 2.89 points (range -10 to 14) on the mJOA scale. One hundred twenty-four patients (68.89%) with mild myelopathy, 201 (72.04%) with moderate myelopathy and 156 (68.42%) with severe disease exhibited clinically meaningful changes in functional status and achieved the MCID of the mJOA score (mild ≥ 1 point, moderate ≥ 2 points, and severe ≥ 3 points). In total, 481 (70.01%) of the 687 patients had an "optimal" surgical outcome, whereas 206 (29.98%) failed to improve by greater than or equal to the MCID. Of these 206 patients, 75 (or 10.92% of the 687 participants) exhibited an improvement less than the MCID, 54 (7.86%) stayed the same, and 77 (11.21%) deteriorated.
Univariate Analysis
Based on univariate analysis, the significant predictors of achieving the MCID on the mJOA scale were younger age (relative risk [RR] 0.918, p < 0.0001); female sex (RR 0.881, p = 0.010); shorter duration of symptoms (RR 0.938, p = 0.0001); nonsmoking status (RR 0.869, p = 0.025); a lower morbidity score (RR 0.966, p = 0.035) and absence of comorbidities; and absence of upgoing plantar responses (RR 0.885, p = 0.028), lower-limb spasticity (RR 0.856, p = 0.0025), and broad-based unstable gait (RR 0.847, p = 0.0007). The associations between this outcome and gastrointestinal disorders, endocrine comorbidities, and hyperreflexia yielded p values < 0.20 and these variables were evaluated in multivariate analysis (Table 3) . 
Multivariate Analysis
The Based on relative risks, the probability of achieving a score greater than or equal to the MCID on the mJOA scale 1) decreases by approximately 6% when a patient has an increased duration of symptoms (i.e., moves from the ≤ 3-month to the 3 to 6-month group); 2) decreases by approximately 8% for every decade increase in age; 3) decreases by 13% when a patient presents with gait impairment (vs no impairment); and 4) decreases by 16% when a patient smokes (Table 4 ). To better interpret the impact of age on outcomes, Table 5 presents, by decade, the percentage of patients who achieved the MCID on the mJOA scale versus those who experienced a decline in function. 
Discussion
This study aimed to identify important predictors of achieving an MCID in functional status following surgery for the treatment of DCM. Based on our results, we found that patients are more likely to exhibit a clinically important improvement if they are younger, do not smoke, have a shorter duration of symptoms, and do not present with a broad-based unstable gait. These factors have previously been identified as important predictors of outcomes, but this is the first study to use a severity-dependent MCID as the dependent variable.
The objectives of surgery are, first, to halt the progression of myelopathy and, second, to improve neurological impairment, functional disability, and quality of life. 8 In our study, 610 patients (88.79%) either stayed the same or improved, while 77 patients (11.21%) deteriorated based on mJOA scale scores. The MCID is a metric that describes a change in status that a patient would define as meaningful. For the mJOA scale, the MCID varies based on severity: patients with more severe myelopathy must make larger gains than those with mild disease to consider their improvement as important. Our model can be used to predict which patients are likely to achieve meaningful improvements in impairment. This information is valuable to the patient and should be used to discuss the probable outcome of the surgery and to appropriately manage expectations. These expectations are closely linked to patient satisfaction, which is of increasing importance in performance-based health care systems. 27 Older patients are less likely to attain an "optimal" outcome on the mJOA scale. Older patients, however, are more severely impaired and therefore require a larger improvement to achieve an MCID. In a study by Nakashima et al., age was identified as an independent predictor of improvement on the mJOA scale, after controlling for baseline severity score, comorbidities, and surgical factors. 16 Elderly patients may not be able to translate neurological improvements to functional recovery as well as younger patients; however, despite this, the elderly do achieve similar improvements in disability and quality of life as evaluated by the Neck Disability Index and SF-36 Physical and Mental Component scores. Along with more severe degenerative changes, the elderly may experience age-related alterations to the composition of their spinal cord. 6 Advancing age is significantly correlated with a decreased density of small myelinated fibers in the corticospinal tract and a reduced number of alpha and gamma motor neurons and small neurons in the intermediate zone of the ventral horn. 24, 25 Other potential explanations for the association between age and outcome include the following: 1) mJOA scoring may be affected by other aspects of the natural aging process, including hip and knee osteoarthritis, sarcopenia, and lumbar canal stenosis; and 2) the elderly have reduced physiological reserves and may be less tolerant of surgery. 16 Throughout the literature, although less effective, surgery still halts disease progression in elderly patients and, in some cases, results in significant improvements in functional status and quality of life. Surgeons should therefore not discriminate on the basis of age but use this information to appropriately manage their patients' expectations. Future studies are required to determine if there is a cut-off age above which the risks of surgery outweigh the benefits.
Patients who smoke are also less likely to achieve an MCID on the mJOA scale. In preclinical studies, tobacco smoking has been associated with increased intervertebral disc degeneration, decreased bone mineral density and reduced microstructural integrity of cerebral white matter. 9, 11, 31 Furthermore, nicotine treatment results in stenosis of and a decrease in the number of vascular bulbs, enlargement of vascular endothelial cells, and reduced blood flow.
11 Smoking may therefore amplify the hypoxic conductions caused by cord compression, reinforce oxidative stress, aggravate edema, and increase the permeability of the blood-spinal cord barrier. 4 In addition, nicotine may worsen the severity of ischemia-reperfusion injury following decompression of the spinal cord, as demonstrated in models of myocardial infarction, brain injury, and necrotizing enterocolitis. 15, 21, 30 In clinical studies, smoking has been shown to be associated with poor wound and bone healing and increased rates of pseudarthrosis and nonunion. 10, 14 Decreased recovery in smokers is therefore likely due to a combination of vascular changes, impaired bone remodeling, and increased risk of complications. Future research is required to evaluate whether smoking cessation improves outcomes.
A longer duration of symptoms and impaired gait may indicate more severe degenerative changes, cord compression, and histological damage. Some DCM patients, however, remain neurologically stable and relatively mild for extended periods of time, whereas others deteriorate rapidly. 26 The duration of symptoms is likely to have a greater impact on outcomes in patients with progression of myelopathy; in these cases, a substantial delay of surgery may prevent optimal outcomes. It is therefore necessary to diagnose myelopathy at an early stage in the disease course and to identify patients at a high risk of progression. Important predictors of neurological deterioration include the following: 1) circumferential cord compression shown on axial MRI; 22 2) an "angular-edged" spinal cord, defined as an acute angled or lateral corner at one or both sides; 23 3) greater range of preoperative neck and head motion; 1 4) lower segmental lordotic angle and greater percentage of vertebral slip; 18 and 5) segmental instability and reduced diameter of the CSF column. 12 These patients with progressive myelopathy should be recommended surgery and counseled as to the risks of delaying intervention.
limitations
This large prospective study represents the first analysis of important predictors of a severity-dependent MCID. This study has certain limitations: 1) the follow-up rate at 24 months was only 74.02%; however, we accounted for missing data using a last-value-carry-forward imputation technique and were able to obtain mJOA scores for 92.46% of the sample; and 2) the reliability of the mJOA and other predictor variables such as duration of symptoms is unknown.
Conclusions
In this large multinational prospective cohort, 70% of patients treated surgically for DCM exhibited a meaningful functional gain on the mJOA scale. The key predictors of achieving an MCID on the mJOA scale were younger age, shorter duration of symptoms, nonsmoking status, and lack of significant gait impairment.
